Connect with us

Business

After LIV Golf, What Will Be the Next Saudi Sports Bet?

Published

on

After LIV Golf, What Will Be the Next Saudi Sports Bet?

When the Saudi Arabian-backed LIV Golf series announced an agreement to join with the PGA Tour on Tuesday, it shocked deal makers across the sports world.

“It’s been a mix of stunned and in disbelief,” Alex Michael, a managing director at the investment bank LionTree, told DealBook about the general reaction.

Industry insiders quickly moved on to wondering which sport could be next.

Saudi Arabia’s enormous sovereign wealth fund, which is known as the Public Investment Fund, or P.I.F., has an appetite for sports. It has made investments in WWE, Formula 1 and a national soccer league (for which the country created an enormous war chest to sign big stars like Lionel Messi, who turned down an offer this week).

But the kingdom’s history of human rights violations has been an obstacle to some deals in the United States. In 2019, the entertainment giant Endeavor returned the fund’s $400 million investment after the murder of the Washington Post columnist Jamal Khashoggi. And until recently, the PGA Tour was eager to use Saudi Arabia’s record against it.

Advertisement

That moral concern seems to have been overridden by the PGA Tour’s business concerns. The deal with LIV Golf came together after the rival circuit picked up traction and lured players away with lofty purses, ultimately making it infeasible for the PGA to compete.

“The Saudis didn’t change history or change who they were,” said Lyle Ayes, chief executive of Verance Capital, which invests in sports. “The deal just made sense.”

Effectively a commercial partnership, the deal may open the door for more sports businesses to accept P.I.F. funds, Ayes said. (Critics would say that was one of Saudi Arabia’s goals in pursuing sports investments in the first place.)

It would be difficult to pull off the LIV Golf playbook in another sport. Baseball faces challenges that would make an investment in a rival league risky: Its fan base is aging, the regional sports model is collapsing, and there aren’t a lot of spare baseball stadiums big enough for a major-league team. A rival to the National Football League would require a large number of players, and past efforts to create competitor leagues have flopped.

The National Basketball Association might be the easiest team league to challenge. Basketball requires fewer players than baseball or football, and courts are fairly easy to find or build. But given how much U.S. players are already paid, it’s unclear what a rival league could offer.

Advertisement

Tennis is probably the best candidate for a rival tour. Like golf, it’s an individual sport, which makes it easier for P.I.F. to lure athletes with big checks. And while there’s a smaller cohort of stars to recruit than in golf, a rival league would need only about a dozen players for an elite tour. Some tennis stars, including fifth-ranked Stefanos Tsitsipas, have already played in Saudi Arabia at the Diriyah tennis exhibition. The threat of Saudi competition is likely one reason the WTA raised money from the private equity firm CVC Capital this year.

Not all options involve poaching athletes. Insiders say they expect the Saudis to begin investing in U.S. sports teams. The N.B.A. has already changed its rules to allow it. And while the N.F.L. doesn’t allow any institutional investors, many expect that to change soon, too.

And while the path didn’t seem available a couple of years ago, the most efficient route for P.I.F. to own a major sports series like the PGA Tour may now be to just acquire one.

“It certainly would be easier to come through the front door,” LionTree’s Michael said.

“If the PGA had, from the get-go, said, ‘Hey, you can value us at some massive premium to what we think we’re valued and give us $3 billion,’ we would have never had LIV Golf.” — Lauren Hirsch

Advertisement

Trump’s latest legal limbo. Former President Donald Trump was charged with felony counts of retaining national defense secrets, conspiring to obstruct justice and making false statements. The charges add to a list of legal challenges for Trump, who leads early polling in the race to become the Republican presidential nominee next year.

Sequoia splits. The Silicon Valley venture capital firm separated into three companies: one focused on the United States and Europe, another on China, and one on India and Southeast Asia. The decision reflected how rising tensions between Washington and Beijing are making it harder for investors to operate in the world’s two biggest economies without facing severe political constraints.

Turmoil at CNN. David Zaslav, head of Warner Bros. Discovery, fired CNN’s chief executive, Chris Licht, after months of disquiet among the news network’s staff, falling ratings and an unflattering profile of the media executive in The Atlantic.

Apple unveils “spatial computing” goggles. The iPhone maker introduced the Vision Pro headset, its first new hardware product in years, generating equal parts excitement and incredulity. Some observers think the device could help make virtual reality and the metaverse mainstream; others were baffled by the price ($3,500) and wondered if it was more hype than transformative tech.

For decades, Saudi Arabia’s sovereign wealth fund — a state-owned investment vehicle that invests in an array of assets, including stocks and private companies — was a quiet investor, less well known than those run by other Persian Gulf nations and Singapore.

Advertisement

And then Mohammed bin Salman rose to power as the kingdom’s de facto ruler in 2015.

Since then, the sovereign fund, the Public Investment Fund, has become the engine of Prince Mohammed’s vast effort to shift Saudi Arabia’s economy away from oil. In a key part of that campaign, Vision 2030, the state fund has poured billions of dollars into foreign businesses, becoming one of the world’s splashiest investors.

The Public Investment Fund has taken multibillion-dollar stakes in Uber and the electric carmaker Lucid; made a $45 billion bet on the Vision Fund, the wildly ambitious tech investment vehicle created by SoftBank; and invested $20 billion in a Blackstone-led infrastructure fund.

Here is how P.I.F.’s deal-making efforts are spread across the globe, including the stakes it has taken as a limited partner in investment firms.

Advertisement

LIV Golf’s deal with the PGA Tour could give Saudi Arabia new prominence in pro sports. It may also bring new prominence to the kingdom’s point man on all types of investments: Yasir al-Rumayyan, the golf- and cigar-loving governor of P.I.F.

A sudden rise to prominence. For much of his career, al-Rumayyan, 53, has operated far from the global stage. A graduate of King Faisal University, he worked his way up the ranks of Saudi brokerages and the kingdom’s financial markets authority. His ascent coincided with the rise of Prince Mohammed, who in 2015 appointed him to lead P.I.F.

Under al-Rumayyan, P.I.F. began flexing its financial might globally, including in the sports world. And cementing al-Rumayyan’s centrality to Saudi Arabia’s economic campaign is his dual role as chairman of Saudi Aramco, the kingdom’s oil giant and the font of its vast wealth. Under him, the fossil fuel producer began trading in the world’s biggest initial public offering, which now commands a $2 trillion market value.

But that new prominence has threatened to put al-Rumayyan in difficult positions: The PGA Tour’s bitter legal fight with LIV could have forced the Saudi financier to sit for a deposition, exposing P.I.F.’s internal workings and the true power that he wields within it. That threat appears to have receded — at least, so long as the deal goes through.

Ultimately, however, al-Rumayyan must still answer to his powerful client. Prince Mohammed has insisted that Saudi Arabia will become a tech-enabled society of the future, abetted by its global deal-making and its staggeringly expensive investments in internal infrastructure projects. The fund has also sought to beat back reports that its investments are the products of freewheeling decision-making, not necessarily beholden to traditional structures like investment committees.

Advertisement

Last year, in the P.I.F.’s only public performance disclosure to date, it said it had made a 25 percent return in 2021. But if its vast investment campaign fails to pay off, it will be al-Rumayyan who is likely to answer for that.

Thanks for reading!

We’d like your feedback. Please email thoughts and suggestions to dealbook@nytimes.com.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Business

Musk and Zuckerberg Reflect New Blows Against D.E.I. Policies

Published

on

Musk and Zuckerberg Reflect New Blows Against D.E.I. Policies

Even before Donald Trump won in November, the conservative backlash against diversity, equity and inclusion policies was going strong.

But new revelations about the next Trump administration’s efforts to constrain what’s commonly known as D.E.I. — and corporate titans’ willingness to put such programs aside — suggest just how strident the pushback will be.

Elon Musk’s cost-cutting initiative is eyeing big cuts to federal diversity programs, according to The Washington Post. The nongovernmental panel, the Department of Government Efficiency, is said to be considering a report by a right-wing civil rights group that claims to have identified more than $120 billion in potential cuts in D.E.I.-related programs.

Among them, according to The Post, are ending programs to benefit Black farmers and businesses, as well as a Biden-era executive order reserving 15 percent of federal contracts for minority-owned businesses. (Separately, the F.B.I. confirmed that it had closed its Office of Diversity and Inclusion, prompting Trump to express anger that it had existed at all.)

The Times shed more light on Mark Zuckerberg’s move to unwind D.E.I. at Meta. In a meeting with Stephen Miller, the influential Trump aide, Zuckerberg signaled that he would do nothing to obstruct the president-elect’s agenda of cracking down on corporate D.E.I. culture. The tech mogul said new guidelines were coming — and soon after announced a rollback of content moderation rules and an end to Meta’s D.E.I. efforts.

Advertisement

Moreover, Zuckerberg blamed Sheryl Sandberg, his former longtime lieutenant who was known for cultural advocacy programs like Lean In, for encouraging employee self-expression in the workplace, The Times adds. (The revelation stoked outrage online.)

The news underscores how defenses of D.E.I. are faltering. Many companies had already been rethinking their commitment to diversity programs before Trump’s victory, especially after the Supreme Court struck down affirmative action at universities. But several corporate giants, including Amazon and McDonald’s, have ended or scaled back such programs post-election.

For some corporations, work on diversity will still take place, using language that isn’t as politically charged. But as corporate leaders respond to pressure from ascendant right-wing activists and seek to get on Trump’s good side, the pressure on D.E.I. isn’t going away.

  • In related news: Meta’s chief technology officer said the company had mishandled how it rolled out changes to diversity policies and content moderation. And for some workers whose careers haven’t advanced how they like, diversity programs may have simply been an excuse to sugarcoat the real reason they were passed over, according to a Wall Street Journal column.

Israel’s security cabinet meets to approve the cease-fire deal. The vote is taking place after Israeli and Hamas negotiators resolved remaining disputes, with ministers expected to clear the agreement this weekend. If approved, Israel would withdraw eastward and both sides would release hostages or prisoners, potentially paving a path to ending the 15-month war.

China’s economy grows, but its population shrinks again. New data showed that the Chinese economy grew 5 percent last year, with increased exports and investment in manufacturing offsetting a slump in construction. But Beijing also disclosed that China’s population fell for a third straight year, despite an unexpected rise in births, portending a longer-term challenge to economic growth.

Advertisement

The Biden administration files a final flurry of regulatory actions. Regulators including the Consumer Financial Protection Bureau, the Environmental Protection Agency, the Federal Trade Commission and the Justice Department struck settlements with companies including American Express, Block, General Motors and Toyota, and recommended charges against the parent of Snapchat. They’re a last burst of oversight actions before the Trump administration, which is expected to take a lighter hand in regulating business, takes office next week.

Bitcoin, stock futures and government bonds — all are rallying modestly on Friday, the final trading day of the Biden era.

Their fortunes appear to be buoyed by renewed bullishness for the next Trump administration, with investors feeling relieved about what they’ve heard from the president-elect’s Cabinet picks on how they intend to operate.

Markets were especially heartened by Donald Trump’s Treasury secretary pick, Scott Bessent. In his confirmation hearing on Thursday, Bessent played down the inflationary risks of Trump’s agenda.

Here are the highlights:

Advertisement
  • Bessent called for renewing and extending Trump’s 2017 tax cuts to avert “economic calamity.” But while he said cutting fiscal spending was also important, he was noncommittal about repealing the country’s debt ceiling and said entitlement programs like Medicare would be safe.

  • He said tariffs should be imposed on select countries to fix trade imbalances or used as leverage to negotiate favorable trade deals. A new round directed at China seems inevitable. In response, China is zeroing in on American chipmakers.

  • Bessent said that Fed independence is key to American fiscal stability. But he warned that Trump, who has long grumbled about high interest rates, was still “going to make his views known.”

  • He demurred on the idea of the Fed creating a digital currency. Still, Bloomberg reports that Trump is expected to designate crypto as a national priority. Speculation is also growing that Trump will greenlight a federal Bitcoin reserve.

Other confirmation hearings raised questions about how the second Trump administration was shaping up. Gov. Doug Burgum of North Dakota, the choice for interior secretary, criticized renewables as part of a wider national “electricity crisis.” The country needed to refocus on fossil fuels to maintain its global lead in energy-intensive sectors like artificial intelligence, he added.

But Lee Zeldin, Trump’s choice to lead the Environmental Protection Agency, dodged questions about Trump’s repeated vows to roll back or scrap the Inflation Reduction Act, Biden’s signature climate legislation.

And Scott Turner, the former N.F.L. player tapped to head the Department of Housing and Urban Development, offered little detail about how he would address a housing crunch. His lack of clarity came as new Freddie Mac data showed mortgage rates hitting an eight-month high.

The surge is pricing some prospective buyers out of the market — despite the Fed having lowered borrowing costs — in a trend that has alarmed some market watchers.


As TikTok nears a potential ban in the United States, elected officials are racing to find ways to delay a crisis that many of them helped stoke by backing the law behind the punishment.

Advertisement

Here’s where things stand.

President Biden is trying to make it Donald Trump’s problem. An administration official told NBC News that the White House was “exploring options” to forestall the app from going dark. Biden also does not plan to fine the companies that host the TikTok app, like Google and Apple, according to NBC News.

That would leave it up to Trump to enforce any punishments against TikTok and its partners. The president-elect has been weighing an executive order to let the app keep running until a U.S. buyer is found, though it is unclear how effective that would be.

Senate Democrats scrambled to arrange a delay. Lawmakers led by Ed Markey of Massachusetts, Chris Van Hollen of Maryland and Cory Booker of New Jersey have sought to pass a bill giving TikTok more time to find a buyer. But Senator Tom Cotton, Republican of Arkansas, objected, citing concerns about dangers posed by the app.

A spokesperson for Senator Chuck Schumer, Democrat of New York, told The Wall Street Journal that the minority leader spoke with Biden on Thursday about creating a delay.

Advertisement

TikTok’s C.E.O. is continuing to court Trump as well. In addition to sitting on the dais for the inauguration with top Cabinet picks and other tech moguls, Shou Chew is hosting a party for pro-Trump creators Sunday night, which will cost TikTok about $50,000 to throw.

Chew is also expected to attend a Trump victory rally on Sunday at the Capital One Arena, sitting in the suite of Raul Fernandez, a Trump donor and a partner at Monumental Sports and Entertainment, the sports team owner.


Elon Musk has famously and unapologetically clashed with regulators and heads of state. But he is coming up against opponents who appear to have touched a nerve: gamers who have questioned his claims to video game mastery.

A recap: Musk has boasted lately on X lately about his gaming prowess, including soaring to the top of the global leader boards in Diablo IV and Path of Exile 2. Such feats require skills, sure, but also a lot of screen time, leading skeptics to question how the C.E.O. of six companies and a key adviser to Donald Trump finds the time.

Online sleuths increasingly believe they have found the answer: They’ve accused Musk of paying others to use his accounts and put in the hours to boost his rankings.

Advertisement

A popular YouTube gaming personality named Asmongold in particular accused Musk of being disingenuous about his rapid rise to the top.

Musk has taken those charges personally. The billionaire has shared videos of himself in action as a way to prove he’s the real deal. Musk also fired back at Asmongold, saying of the YouTuber, “he is NOT good at video games.”

Others came to Asmongold’s defense, using X’s Community Notes feature to annotate Musk’s posts.

Given the level of discussion online, this spat feels like it’s far from over.

Deals

Advertisement
  • Rio Tinto and Glencore reportedly held talks last year about a deal, which would have combined two of the world’s biggest miners, though discussions aren’t currently active. (Bloomberg).

  • Junior investment bankers beware: Artificial intelligence tools can write 95 percent of an I.P.O. prospectus in minutes, according to David Solomon, Goldman Sachs’s C.E.O. (FT)

Politics, policy and regulation

  • Meet Ken Howery, the tech investor and friend of Elon Musk who will spearhead any deal talks with Denmark over Greenland. (NYT)

  • A group representing Capitol Hill staffers who work for progressive lawmakers is pushing for a 32-hour workweek. (Politico)

Best of the rest

  • A SpaceX rocket broke up on Thursday during a test flight, forcing the F.A.A. to divert several commercial flights to avoid the debris. (CNBC)

  • David Lynch, the director behind classic movies and TV shows including “Blue Velvet,” “Mulholland Drive” and “Twin Peaks,” has died. He was 78. (NYT)

We’d like your feedback! Please email thoughts and suggestions to dealbook@nytimes.com.

Continue Reading

Business

Column: A stem cell clinic tees up a Supreme Court challenge to rules protecting patients' health and safety

Published

on

Column: A stem cell clinic tees up a Supreme Court challenge to rules protecting patients' health and safety

For years, the Food and Drug Administration has taken up arms against clinics hawking unproven and ineffective stem cell treatments to desperate patients looking for cures of intractable diseases and conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis and even erectile dysfunction.

As the FDA has repeatedly cautioned, there is no scientifically validated evidence that these treatments work. They’re typically not covered by insurance. For the clinics, however, they’re money-makers, with fees of $9,000 or more per treatment; the clinics often recommend multiple treatments.

But now the FDA’s campaign against these bogus therapies is facing serious headwinds on two fronts.

[The FDA is] likely to be subjected to enormous political pressure during Trump 2.0 to weaken oversight of cell and regenerative products.

— Paul S. Knoepfler, UC Davis

Advertisement

One is the Supreme Court. A California stem cell network that recently lost a lawsuit brought by the FDA has signaled that it intends to appeal to the Supreme Court. It’s far from certain that the court will take up the appeal, at this stage — but a majority of the justices have looked favorably on efforts to rein in administrative agencies such as the FDA.

“I think it’s highly unlikely … but not impossible” that the court will take up the stem cell case, says Henry T. Greely, an expert in the legal issues involving bioscientific technologies.

The case doesn’t have the customary hallmarks of cases that warrant Supreme Court action, Greely told me, such as disagreements among appellate circuits requiring resolution. But it may suit the ideological bent of four justices — the minimum number required to place a case on the Supreme Court docket.

“Some of these justices really hate administrative agency power,” Greely says.

Advertisement

In a landmark ruling last year, the Supreme Court struck down a 40-year-old precedent—the Chevron doctrine — that required courts to accept federal agencies’ interpretations of the laws they administer as long as their interpretations weren’t openly unreasonable. That sharply narrowed agency authority. The FDA has ranked high on the list of agencies that conservatives see as exercising excessive authority.

It may not take a Supreme Court decision to hamper the FDA’s campaign against bogus stem cell treatments.

“Just the possibility that [the Supreme Court] could take this case may have a chilling effect on FDA activity in the stem cell clinic space,” Paul S. Knoepfler, a UC Davis biologist who has assiduously tracked the industry, told me. Even without the case, he says, the FDA is “likely to be subjected to enormous political pressure during Trump 2.0 to weaken oversight of cell and regenerative products.”

That brings us to the second threat, coming from Donald Trump’s nominee as secretary of Health and Human Services, Robert F. Kennedy Jr. Even before his nomination, Kennedy made clear that he was girding to go to war against the FDA, which would come under his jurisdiction at HHS.

In an Oct. 25 tweet, he declared “FDA’s war on public health is about to end.” He specifically accused the agency of “aggressive suppression” of stem cells as well as “psychedelics, peptides, … raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine … and anything else that advances human health and can’t be patented by Pharma.”

Advertisement

Kennedy wasn’t clear what he meant by his reference to stem cells or whether he was referring to the unproven stem cell treatments marketed by the clinics facing FDA regulation.

Many of the other items in his litany have been shown to be ineffective for their marketed purposes — ivermectin and hydroxychloroquine, for example, have been touted as treatments for COVID-19 even though scientific studies have shown them to be useless against the disease. I asked Kennedy to clarify his reference to stem cells but haven’t received a reply.

Here’s a brief primer on what these clinics are selling. Typically, their method involves removing fat cells from a customer via liposuction, treating the fat ostensibly to extract stem cells, and injecting those cells into the customer’s body.

For instance, Cell Surgical Network, a defendant in the FDA’s California case, boasts of offering “innovative solutions” for spine disease, knee problems and other orthopedic conditions; lupus, Crohn’s and other autoimmune diseases; ALS, Parkinson’s and multiple sclerosis; cardiac conditions; and glaucoma, among other issues. None of these claims has been supported by scientific research.

The only stem cell products the FDA has approved for use are stem cells extracted from umbilical cord blood, and then only for rare blood disorders.

Advertisement

Like other clinics, Cell Surgical has asserted that its products are exempt from oversight because, as reimplantations of a customer’s own tissue, they don’t meet the law’s definition of “drugs.”

They also claim the “same surgical procedure” exemption from FDA regulation, which the agency typically applies to procedures in which a patient’s tissue is given only minimal processing before being used, such as in skin grafting or coronary artery bypass surgery. The FDA holds that the stem cell clinics subject the tissues to significant processing and that the procedures are separate surgical events.

Before the FDA acted, both the Florida and California clinic networks had been operating for years. The Florida company had been operating since at least 2014, and Lander and Berman had founded their California Stem Cell Treatment Center in Rancho Mirage in 2010. By 2018, the FDA said in its lawsuit, Lander had claimed that affiliated clinics had administered the technique he and Berman developed to more than 6,000 patients.

Yet the FDA sometimes seems to be fighting a losing battle, or at least a whack-a-mole battle, against clinics offering dubious stem cell treatments. There are just too many — more than 1,000, by Knoepfler’s reckoning — making pitches to desperate customers seeking cures against intractable conditions.

That has left things up to state and local regulators, but the record there is spotty. A notable recent success can be chalked up to Georgia Atty. Gen. Chris Carr, who announced on Jan. 8 that in conjunction with the Federal Trade Commission he had obtained judgments totaling more than $5.1 million from the operators of bogus stem cell clinics. The sum includes refunds of more than $3.3 million for 479 customers, most of whom were “older or disabled adults” who had been “sold expensive, unproven stem cell products.”

Advertisement

In June 2019, federal Judge Ursula Ungaro of Miami ordered U.S. Stem Cell of Florida effectively shut down, siding with the FDA in a lawsuit the agency had filed in May 2018.

The FDA’s case against California-based Cell Surgical Network and its affiliates took a somewhat different course. The agency filed suit in California federal court against the network and its physician-proprietors, Elliott B. Lander and the late Mark Berman, the same day it sued the Florida firm. But it lost at the trial stage in August 2022, when federal Judge Jesus Bernal of Riverside accepted the defendants’ claim that they were entitled to the “same surgical procedure” exemption from FDA oversight.

Bernal’s decision, however, was overturned last September by the San Francisco-based 9th Circuit Court of Appeals, which found in a 3-0 ruling that the FDA’s interpretation of the law “is the only interpretation that makes sense.” The appeals court sent the case back to Bernal with instructions to reconsider the case in light of its finding.

That’s where things stood until Jan. 6, when Cell Surgical Network and its affiliated defendants asked the appellate court to suspend its order to remand the case to Bernal, pending an appeal to the Supreme Court. The FDA opposed the motion, arguing that the Supreme Court is unlikely to take up the case. The appellate court rejected the network’s motion Tuesday, but the network hasn’t indicated that it intends to drop the Supreme Court appeal. I asked its lawyers if their plans have changed but haven’t received a reply.

As I’ve written before, undermining the FDA’s authority has been a right-wing project for years. That’s because the agency’s duty is to stand in the way of businesses desiring to push unsafe and ineffective nostrums at unwary consumers, and also in the way of a perverse idea that personal freedom includes the freedom to be gulled by charlatans.

Advertisement

In 2018, then-President Trump signed a right-to-try law that purportedly gave victims of terminal diseases access to experimental treatments that might save them.

But despite claims that it was designed as a “compassionate measure” for terminal patient, the law was a scam perpetrated by the Koch network and its allies, aimed at undermining the FDA’s authority to make sure our drugs are safe and effective. Sen. Ron Johnson (R-Wis.) ultimately gave the game away, informing then-FDA Commissioner Scott Gottlieb, a critic of the law, that its purpose was to “diminish the FDA’s power over people’s lives, not increase it.”

In 2023, GOP-appointed judges on the right wing-dominated 5th Circuit Court of Appeals ruled that the FDA had exceeded its authority in advising against the use of ivermectin against COVID. “The FDA can inform,” the court said, “but it has identified no authority allowing it to recommend consumers ‘stop’ taking medicine.” (Emphasis in the original.)

There may not be much distance between that finding by the 5th Circuit and a decision by the current Supreme Court majority that the FDA overstepped its bounds in not only informing consumers of the dangers of taking unproven and even dangerous stem cell treatments, but blocking the treatments by seeking to put clinics that sell them.

“MAGA loves stem cell clinics,” Greely says. “Why? It gives people a chance to make a lot of money, and because it’s a change for people to say ‘no bureaucrat is going to tell me what to do.’”

Advertisement

If the trend continues along these lines, you can expect more providers collecting more dollars by pushing worthless therapies to desperate customers. The threat to Americans’ health will be very real indeed.

Continue Reading

Business

China’s Population Declines for 3rd Straight Year

Published

on

China’s Population Declines for 3rd Straight Year

To get its citizens to have more children and stop its population from shrinking, China has tried it all, even declaring having babies an act of patriotism. And yet, for the third year in a row, its population got smaller.

Not even a surprise uptick in the number of babies born, a first in seven years, could reverse the course of an aging and declining population.

China is staring down a longer term baby bust that is rippling through the economy. Hospitals are shutting their obstetrics units, and companies that sold baby formula are idling factories. Thousands of kindergartens have closed and more than 170,000 preschool teachers lost their jobs in 2023.

The country’s birthrate, as one former kindergarten in the southern city of Chongqing put it, “is falling off a cliff.” Enrollments in China’s kindergartens plummeted by more than five million in 2023, according to the most recently available data.

On Friday, the National Bureau of Statistics reported that 9.54 million babies were born last year, up slightly from 9.02 million in 2023. Taken together with the number of people who died over 2024 — 10.93 million — China’s population shrank for a third straight year.

Advertisement

The small bump in newborns, in part because it was the auspicious Year of the Dragon in the Chinese zodiac, didn’t change the broader trajectory, experts said. China’s childbearing population is declining and young people are reluctant to have children.

“In the medium and long term, the annual number of births in my country will continue to decline,” said Ren Yuan, a professor at Fudan University’s Institute of Population Studies.

The lack of babies is adding to China’s economic challenges. A shrinking working-age population is straining an underfunded pension system, and an aging society is leaning on a creaking health care system. China also reported on Friday that the economy grew by 5 percent in 2024, a number that was in line with expectations but that many experts said did not fully reflect a crisis of confidence among households reeling from a multiyear property crisis.

To encourage people to have more babies, the authorities are offering tax benefits, cheaper housing and cash. Cities are promising to cover the cost of in vitro fertilization. In some parts of the country, they are even promising to get rid of restrictions that penalize single mothers.

The government has called on local officials to put in place early-warning systems to monitor big changes in population at the village and town levels around the country. Some officials are even knocking on doors and calling women to inquire about their menstrual cycles.

Advertisement

Companies are also getting involved. In 2023, the travel site Trip.com started paying employees nearly $1,400 a year for each newborn until the age of 5. Last week, the founder of electric vehicle maker XPeng said he would give employees nearly $4,100 if they had a third child.

“We want our employees to have more kids,” said He Xiaopeng, the founder, in a video posted on social media. “I think the company should take care of the money, so employees can have children.”

The problem is not unique to China, which in 2023 was passed by India as the world’s most populous nation. Falling birthrates are often a measure of a country’s move up the economic ladder because fertility rates tend to fall as incomes and education levels go up. But China’s sudden decline in population arrived much sooner than the government had expected. Many families are earning more money than they were a decade ago, but have lost income because of the housing crisis.

Officials have long feared the day when there will not be enough workers to support retirees. Now the government has less time to prepare. More than 400 million people will be 60 or older in the next decade.

China is facing two challenges on this front. Its public pension system is severely underfunded and many young people are reluctant — or are unable — to contribute. A low retirement age has made things worse. After years of deliberation, the government decided on a 15-year plan to gradually increase the official age to 63 for men, 58 for women in office jobs and 55 for women who work in factories. The changes took effect this month.

Advertisement

The party only loosened birth restrictions in 2015 to allow families to have two children, an easing that created a sudden boom. Hospitals had to add beds in the corridors because there weren’t enough.

But the moment was short-lived. By 2017, births started declining every year until last year.

In 2021, panicked officials loosened China’s birth policy again, allowing couples to have three children. It was too late. The next year, so few babies were born that the population began to shrink for the first time since the Great Leap Forward, Mao Zedong’s failed experiment that resulted in widespread famine and death in the 1960s.

China has one of the lowest fertility rates in the world, far below what demographers refer to as the replacement rate required for a population to grow. This threshold requires every couple, on average, to have two children.

Experts said the number of births would likely continue to fluctuate.

Advertisement

“For a country of 1.4 billion a half million more births is not much of a rebound at all,” Wang Feng, a professor of sociology at the University of California, Irvine. “This is in comparison to the lowest year, in 2023 when the pandemic certainly put a pause on childbearing.”

Many young Chinese people are quick to rattle off reasons not to have children: the rising cost of education, growing burdens of taking care of their aging parents and a desire to live a lifestyle known as “Double Income, No Kids.”

For women, the sentiment is especially strong. Daughters who were the only children in their families received education and employment opportunities their parents often did not. They have grown up to become empowered women who see Mr. Xi’s appeals to them to do their patriotic duty and bear children as one step too far. Many of these women have said that deep-seated inequality and insufficient legal protections have made them reluctant to get married.

The steep drop in babies is having a drastic effect on health care, education and even the consumer market. Companies that once minted money selling baby formula to feed a baby boom are now making shakes with calcium and selenium for older adults with brittle bones.

Nestlé, the world’s largest food company, is shutting a factory for the China market that employs more than 500 people halfway across the world in Europe. The company will focus on selling premium baby products and expanding its offering in adult nutrition in China, a spokesman said.

Advertisement

The pressure on China’s health care system is even more pronounced. Dozens of hospitals and maternal health clinic chains have reported closing over the past two years.

On social media forums, nurses specializing in obstetrics have talked about low pay and lost jobs. One doctor told state media that being in obstetrics, once considered an “iron rice bowl” position with guaranteed job security, had become a “rusty iron rice bowl.”

And some smaller hospitals have stopped paying their staff, Han Zhonghou, a former official at a hospital in northern China, told a Chinese magazine.

“Life for maternal and child hospitals,” Mr. Han said, “is getting harder and harder by the year.”

Advertisement
Continue Reading

Trending